GuardDose

Patient database

0 records

MRN	Name	Age / Sex	CrCL	Pop	Regimen	CL prior	CL MAP	AUC₂₄	Outcome	Saved by	Updated

No data yetSave or upload cases to see analytics.

Upload cases

Drop a CSV or Excel file here, or click to choose
One row per patient. Columns are matched by name (case-insensitive).

Treat all rows as HM population

Required and optional columns

Requiredage, weight_kg, scr_umol or crcl_ml_min, dose_mg, tau_h Recommendedpatient_id (MRN), sex (M/F), height_cm, tinf_h, ward Optional TDMtrough (mg/L), trough_time_h (h after infusion start) — runs MAP automatically Optionalfirst_name, last_name, population (general/hm), notes

Rows missing required values are reported and skipped; the rest are saved. Existing MRNs are updated.

Users

Name	Email	Role	Ward	Status	Last sign-in

Audit log

Time	User	Action	Resource	Detail	IP

GuardDose v6.0

Model-informed precision dosing platform for intravenous vancomycin in adults, developed as part of a doctoral research programme with institutional ethics approval. Demonstration version.

Engines

PopPK (general)One-compartment, first-order elimination, IOV on CL. n = 558, 773 occasions, 905 concentrations; external n = 210. Monolix 2024R1, SAEM. CL 3.48 L/h (CrCL^0.60, Age^−0.24), V 93.41 L (Age^1.00), ω_CL 0.37, ω_V 0.38, γ 0.16, b 0.15. HM modelHaematological malignancy / febrile neutropenia. n = 207; external n = 53. CL 5.11 L/h (CrCL^0.50), V 36.83 L, ω_CL 0.26, ω_V 0.25, b 0.13. Ridge ML19 features from 7 routine variables; target ln(CL) derived with V = 0.7 L/kg; α 0.126. External R² 0.582, MAE 0.998 L/h, bias +9.7% (PopPK: 0.521, 1.100 L/h, +15.0%). MAP BayesianFull dose-history superposition; proportional residual error; Nelder–Mead with restarts; posterior SD from the Hessian (Laplace approximation); 90% CI on CL and AUC₂₄. ConcordancePopPK and ridge a priori clearances compared; <20% concordant, 20–40% moderate, >40% discordant. Weighted prior uses inverse external-RMSE weights (PopPK 0.47, ridge 0.53).

Clinical use

Decision support only. Recommendations require review by a clinical pharmacist. Target AUC₂₄ 400–600 mg·h/L assumes MIC ≤ 1 mg/L (Rybak et al., 2020). Reassess renal function and re-run MAP after any change in SCr > 25%.

Developer: Dr. Abdullah M. Alzahrani, PharmD, MSc, BCPS · Supervisors: Prof. Samer Alharthi, Dr. Maher Alahmadi.

Step 1 — Population model

Patient

Renal function

Vancomycin regimen

Patient database

Exposure outcome

AUC₂₄ distribution

Cases by ward

Cases per month

By user

Upload cases

Required and optional columns

Preview

Users

Audit log

GuardDose v6.0

Engines

Clinical use

Step 1 — Population model

Patient

Renal function

Vancomycin regimen

Patient database

Exposure outcome

AUC₂₄ distribution

Cases by ward

Cases per month

By user

Upload cases

Required and optional columns

Preview

Users

Audit log

GuardDose v6.0

Engines

Clinical use

Add user

Manage user

Change password